NEW: COVID-19 vaccine candidate shows promise in early results of phase 1 trial, with patients who received two doses of the vaccine developing neutralizing antibodies. The drug is now being tested in larger studies.
The goal of phase 1 trials is to evaluate the safety of a new drug in a small group of participants, not effectiveness. Phase 2 trials study whether a drug works.
In total, 45 study participants each received two doses of the vaccine, about a month apart. Participants were given one of three dosage levels: 25 micrograms, 100 micrograms and 250 micrograms. Moderna said those who received the two lower doses developed COVID-19 antibodies about two weeks after the second dose. Final information on the 250 microgram dosing was not available.The only side effect, the company reported, was redness around the area where people got the shot.Related
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna Says Initial Covid-19 Vaccine Results Are PositiveModerna said human subjects in a Phase 1 trial of a candidate Covid-19 vaccine produced immune responses that were a positive sign of the vaccine’s potential to prevent infection with the new coronavirus
Read more »
With 19 Confirmed COVID-19 Cases And No Deaths, Laos To Loosen LockdownLaos has zero reported COVID-19 deaths and confirmed cases have held steady at 19 for over a month. Now, officials are further lifting lockdown restrictions.
Read more »
Moderna's COVID-19 vaccine shows early promise; shares soarEarly data from Moderna Inc's COVID-19 vaccine, the first to be tested in the United States, showed that it produced protective antibodies in a small group of healthy volunteers, the company said on Monday.
Read more »
Martin Shkreli Denied Early Prison Release Over COVID-19The hated Pharma Bro will continue to serve his sentence in prison.
Read more »
Llama Antibodies Neutralize Virus That Causes COVID-19, New Research ShowsA new study shows that antibodies from llamas can neutralize the virus that causes COVID-19. It started in 2016 with a llama named Winter — who's now 'grazing peacefully on a farm in Belgium,' one researcher tells vprnet.
Read more »
Experts: COVID-19 shows U.S., U.K. are vulnerable to biological terrorismThe coronavirus pandemic has exposed a structural vulnerability to biological attacks in the U.S. and Europe that requires urgent government action, experts say.
Read more »